273 related articles for article (PubMed ID: 18801766)
21. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
22. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization.
Yodoi Y; Tsujikawa A; Nakanishi H; Otani A; Tamura H; Ojima Y; Hayashi H; Yoshimura N
Am J Ophthalmol; 2009 May; 147(5):816-24, 824.e1. PubMed ID: 19211092
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
Sakaguchi H; Ikuno Y; Gomi F; Kamei M; Sawa M; Tsujikawa M; Oshima Y; Kusaka S; Tano Y
Br J Ophthalmol; 2007 Feb; 91(2):161-5. PubMed ID: 16914470
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
25. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
Arias L; Planas N; Prades S; Caminal JM; Rubio M; Pujol O; Roca G
Br J Ophthalmol; 2008 Aug; 92(8):1035-9. PubMed ID: 18653595
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up.
Chen CH; Wu PC; Chen YJ; Liu YC; Kuo HK
J Ocul Pharmacol Ther; 2011 Aug; 27(4):395-400. PubMed ID: 21770740
[TBL] [Abstract][Full Text] [Related]
28. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.
Chan WM; Lai TY; Wong AL; Liu DT; Lam DS
Br J Ophthalmol; 2007 Feb; 91(2):174-9. PubMed ID: 16987898
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results.
Silva RM; Ruiz-Moreno JM; Rosa P; Carneiro A; Nascimento J; Rito LF; Cachulo ML; Carvalheira F; Murta JN
Retina; 2010 Mar; 30(3):407-12. PubMed ID: 20094007
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
31. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.
Baba T; Kubota-Taniai M; Kitahashi M; Okada K; Mitamura Y; Yamamoto S
Br J Ophthalmol; 2010 Jul; 94(7):864-70. PubMed ID: 19965833
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
33. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Arevalo JF; Ziemssen F; Mehio-Sibai A; Mackensen F; Adan A; Chan WM; Ness T; Banker AS; Dodwell D; Chau Tran TH; Fardeau C; Lehoang P; Mahendradas P; Berrocal M; Tabbarah Z; Hrisomalos N; Hrisomalos F; Al-Salem K; Guthoff R
Am J Ophthalmol; 2009 Aug; 148(2):310-316.e2. PubMed ID: 19427992
[TBL] [Abstract][Full Text] [Related]
34. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum.
Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP
Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study.
Gharbiya M; Allievi F; Conflitti S; Esposito M; Scavella V; Moramarco A; Cruciani F
Clin Ter; 2010; 161(3):e87-93. PubMed ID: 20589348
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
[TBL] [Abstract][Full Text] [Related]
40. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
